Kairos Pharma, Ltd.
KAPAHealthcare|Biotechnology|US
$0.49
+0.03 (+7.33%)
DCF Value
$1.64
Tangible Book / Share
$1.37
Cash / Share
$0.86
Financials
Financial Snapshot
Market Cap
$1.7M
Enterprise Value
-$974.3K
Revenue (TTM)
$0.00
Net Income (TTM)
-$5.8M
Cash & Investments
$2.6M
Net Cash
$2.6M
Free Cash Flow (TTM)
-$4.0M
Operating CF (TTM)
-$4.0M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$2.6M
Quarterly Burn
$992.5K
Monthly Burn
$330.8K
Est. Runway
~2.6 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $14.3K | $73.0K | $437.0K | $93.0K | $1.3M | $4.5M | $2.6M | |
| Operating Cash Flow | -$38.5K | -$412.0K | -$353.0K | $81.0K | -$4.0M | -$3.4M | -$4.0M | |
| Free Cash Flow | -$38.5K | -$412.0K | -$353.0K | $81.0K | -$4.0M | -$3.4M | -$4.0M | |
| Capital Expenditure | $5.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $37.0K | $580.0K | $717.0K | -$425.0K | $5.1M | $6.7M | $3.6M |
R&D Spending
R&D (TTM)
$2.4M
R&D Intensity
—
R&D Growth vs Prior
+14.7%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $20.0K | $183.0K | $87.0K | $82.0K | $414.0K | $2.1M | $2.4M | |
| SG&A | $1.0M | $1.7M | $324.0K | $1.5M | $1.8M | $3.4M | $3.4M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $98.0K | $160.0K | $160.0K | $160.0K | $0.00 | -$80.0K | |
| Gross Profit | $0.00 | -$98.0K | -$160.0K | -$160.0K | -$160.0K | $0.00 | $80.0K | |
| R&D | $20.0K | $183.0K | $87.0K | $82.0K | $414.0K | $2.1M | $2.4M | |
| SG&A | $1.0M | $1.7M | $324.0K | $1.5M | $1.8M | $3.4M | $3.4M | |
| Operating Income | -$1.0M | -$1.9M | -$571.0K | -$1.7M | -$2.3M | -$5.6M | -$6.0M | |
| Interest Expense | $5.4K | $202.0K | $479.0K | $98.0K | $859.0K | $0.00 | $0.00 | |
| Pretax Income | -$1.1M | -$2.1M | -$1.1M | -$1.8M | -$2.6M | -$5.4M | -$5.8M | |
| Net Income | -$1.1M | -$2.1M | -$1.1M | -$1.8M | -$2.6M | -$5.4M | -$5.8M | |
| EPS (Diluted) | -0.66 | -1.19 | -0.70 | -1.19 | -1.61 | -2.10 | -1.94 | |
| EBITDA | -$1.0M | -$1.8M | -$411.0K | -$1.6M | -$1.6M | -$5.3M | -$5.7M | |
| Shares Out. (M) | 1.60 | 1.83 | 1.46 | 1.48 | 1.62 | 2.63 | 3.06 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.3K | $73.0K | $437.0K | $93.0K | $1.3M | $4.5M | $2.6M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $14.3K | $73.0K | $437.0K | $101.0K | $4.2M | $5.4M | $3.2M | |
| Total Assets | $14.3K | $775.0K | $1.0M | $965.0K | $6.2M | $6.5M | $4.5M | |
| Total Current Liabilities | $357.1K | $1.9M | $1.6M | $2.4M | $992.0K | $199.0K | $265.0K | |
| Long-Term Debt | $0.00 | $0.00 | $582.0K | $638.0K | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $357.1K | $1.9M | $2.2M | $3.0M | $1.4M | $199.0K | $265.0K | |
| Stockholders' Equity | -$342.8K | -$1.2M | -$1.2M | -$2.1M | $4.8M | $6.3M | $4.2M | |
| Retained Earnings | -$1.2M | -$3.4M | -$4.4M | -$6.2M | -$8.8M | -$14.3M | -$17.3M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$38.5K | -$412.0K | -$353.0K | $81.0K | -$4.0M | -$3.4M | -$4.0M | |
| Capital Expenditure | $5.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$38.5K | -$412.0K | -$353.0K | $81.0K | -$4.0M | -$3.4M | -$4.0M | |
| Investing Cash Flow | $0.00 | -$109.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $37.0K | $580.0K | $717.0K | -$425.0K | $5.1M | $6.7M | $3.6M | |
| Issuance of Stock | $0.00 | $250.0K | -$57.0K | -$425.0K | $5.5M | $3.1M | $4.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $50.0K | $330.0K | $895.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $800.0K | $300.0K | $0.00 | $913.0K | $218.0K | $0.00 | $259.0K | |
| Net Change in Cash | -$1.5K | $59.0K | $364.0K | -$344.0K | $1.2M | $3.2M | -$408.0K |
Dilution Tracker
Shares outstanding grew 64.3% over 5 years — significant dilution
Shares Outstanding
3M
5-Year Share Growth
+64.3%
Stock Issuance (TTM)
$4.0K
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.60 | 1.83 | 1.46 | 1.48 | 1.62 | 2.63 | 3.06 | |
| Change vs Prior % | — | 14.5% | -20.3% | 1.4% | 9.4% | 62.3% | 16.2% | |
| Stock Issuance | $0.00 | $250.0K | -$57.0K | -$425.0K | $5.5M | $3.1M | $4.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $800.0K | $300.0K | $0.00 | $913.0K | $218.0K | $0.00 | $259.0K |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| ROE % | 306.7% | 183.8% | 89.1% | 87.2% | -54.5% | -85.9% | -98.8% | |
| ROA % | -7348.0% | -276.8% | -101.4% | -187.8% | -41.9% | -83.3% | -130.3% | |
| ROIC % | 357.2% | 246.9% | 96.3% | 119.0% | -44.9% | -87.9% | -143.9% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | -63.3% | 0.0% | 0.0% | 100.0% | |
| Operating Income | 0.0% | -85.8% | 70.6% | -200.2% | -36.7% | -137.8% | |
| Net Income | 0.0% | -104.0% | 51.0% | -72.6% | -43.7% | -109.3% | |
| EPS (Diluted) | 0.0% | -81.4% | 41.2% | -70.0% | -35.3% | -30.4% | |
| Operating Cash Flow | 0.0% | -969.2% | 14.3% | 122.9% | -4982.7% | 13.0% | |
| Free Cash Flow | 0.0% | -969.2% | 14.3% | 122.9% | -4982.7% | 13.0% | |
| R&D Expense | 0.0% | 815.0% | -52.5% | -5.7% | 404.9% | 415.7% | |
| SG&A Expense | 0.0% | 62.0% | -80.5% | 354.3% | 20.2% | 94.3% | |
| Total Assets | 0.0% | 5316.6% | 33.7% | -6.9% | 544.1% | 5.2% | |
| Book Value / Share | 0.0% | -197.3% | -26.7% | -73.8% | 310.1% | -18.2% | |
| Debt | 0.0% | 660.0% | 54.2% | 8.9% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | 14.5% | -20.3% | 1.4% | 9.4% | 62.3% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.36
EV/EBITDA0.17
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.64
Tangible Book / Share
$1.37
Net Current Assets / Share
$0.86
Graham Net-Net
$0.77
Cash / Share
$0.86
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -27.75 | -15.29 | -26.00 | -15.29 | -6.61 | -2.37 | -0.25 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -85.06 | -28.61 | -22.57 | -12.99 | 3.61 | 2.06 | 0.36 | |
| EV/EBITDA | -27.91 | -18.26 | -65.12 | -17.72 | -10.09 | -1.63 | 0.17 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-5.21
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Net Income | -$6.8M | -$12.3M | -$13.5M |
| EPS | $-2.59 | $-4.69 | $-5.11 |
| # Analysts (EPS) | 1 | 1 | 2 |